|
|
SPOT ON
|
|
German health care reform hinders rational therapy |
|
Myocardial infarction with heart failure: Valsartan (e.g. DIOVAN) and captopril (e.g. LOPIRIN) equally effective? |
|
|
NEW ON THE MARKET
|
|
Keep off: Parathyroid hormone fragment teriparatide (FORSTEO) for osteoporosis
|
|
|
THERAPIES FROM A CRITICAL VIEW POINT
|
|
Selective digestive tract decontamination in intensive care patients? Not for routine use!
|
|
|
REVIEW
|
|
Antioxidants: How useful? (II)
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
VALIANT: Misleading promotion for DIOVAN (valsartan)
Theophylline preparation THROMPHYLLIN especially inexpensive?
Bayer Vital: Payed post-graduate educational programme for moxifloxacin (AVALOX) on the internet
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Visual disturbance associated with rofecoxib (VIOXX) and celecoxib (CELEBREX)
Dysgeusia due to clopidogrel (ISCOVER, PLAVIX) or ticlopidine (e.g. TIKLYD)
|
|
|
SIDE EFFECTS
|
|
SSRI and related antidepressants: Warning on suicidality in children
|
|